KIORA PHARMACEUTICALS INC
Small molecule therapeutics for retinal diseases
- Sector
- Biotech
- Headquarters
- ENCINITAS, CA
- Founded
- 2004
- Latest Form D
- $5M, Apr 2026
- Total capital
- $68.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $68.5M
- 17 Form D · last Apr 2026
- 6 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2022
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 16th filing$5M
- Private capital raisedForm D · SEC · 15th filing$15M
- Offering registeredForm D · SEC · 14th filing$10M
- Private capital raisedForm D · SEC · 13th filing$200K
- Private capital raisedForm D · SEC · 12th filing$67K
- Private capital raisedForm D · SEC · 11th filing$10.8M
- Private capital raisedForm D · SEC · 10th filing$8M
- Private capital raisedForm D · SEC · 9th filing$3.2M
- Private capital raisedForm D · SEC · 8th filing$1.9M
- Private capital raisedForm D · SEC · 7th filing$3.8M
- Private capital raisedForm D · SEC · 6th filing$2.6M
- Private capital raisedForm D · SEC · 5th filing$995K
- Private capital raisedForm D · SEC · 4th filing$969K
- Private capital raisedForm D · SEC · 3rd filing$4.5M
- Private capital raisedForm D · SEC · 2nd filing$11.1M
- Private capital raisedForm D · SEC · 1st filing$490K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Aron ShapiroDirectorNamed in SEC Form D filings
- Brian StremExecutive Officer, DirectorNamed in SEC Form D filings
- Carmine StengoneDirectorNamed in SEC Form D filings
- David HollanderDirectorNamed in SEC Form D filings
- Eric DanielsExecutive OfficerNamed in SEC Form D filings
- Erin ParsonsDirectorNamed in SEC Form D filings
Show all 11 people
- Kenneth GayronDirectorNamed in SEC Form D filings
- Lisa Walters-HoffertDirectorNamed in SEC Form D filings
- Melissa ToscaExecutive OfficerNamed in SEC Form D filings
- Paul ChaneyDirectorNamed in SEC Form D filings
- Praveen TyleDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- PendingCompositions And Methods For Treatment Of Ocular DiseasesUSPTOApplication 17827154
- GrantedCompositions and Methods for Treatment of Ocular DiseasesUSPTOUS 11,376,214
- PendingCompositions And Methods For Treating Ocular Disease By Contact Lens Mediated Drug DeliveryUSPTOApplication 17209645
Show all 6 patent records
- Compositions And Methods For Treatment Of Ocular DiseasesSep 15, 2022 · Application 17827154Pending
- Compositions and Methods for Treatment of Ocular DiseasesJul 5, 2022 · US 11,376,214Granted
- Compositions And Methods For Treating Ocular Disease By Contact Lens Mediated Drug DeliverySep 30, 2021 · Application 17209645Pending
- Compositions and Methods for Treatment of Ocular ConditionsSep 23, 2021 · Application 17208381Pending
- Compositions And Methods For Treating Ocular Disease By Contact Lens Mediated Drug DeliveryApplication PCTUS2021023572Pending
- Compositions And Methods For Treatment Of Ocular ConditionsApplication PCTUS2021023438Pending
Related companies, and why
- Swan NeuroTech, Inc.Similar federal contract value in Biotech · null in contracts
- DalCor Pharmaceuticals US, LLCSimilar federal contract value in Biotech · null in contracts
- AMARIN CORP PLC\UKSimilar federal contract value in Biotech · null in contracts
- Sagimet Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Scienture Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Aloe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .